SEARCH

SEARCH BY CITATION

References

  • Ajayi AA, Ogungbade GO, Okorodudu AO. Sex hormone regulation of systemic endothelial and renal microvascular reactivity in type-2 diabetes: studies in gonadectomized and sham-operated Zucker diabetic rats. Eur J Clin Invest. 2004;34: 349357.
  • Akishita M., Hashimoto M., Ohike Y., Ogawa S., Iijima K., Eto M., Ouchi Y.. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res. 2007;30: 10291034.
  • Allan CA, Strauss BJG, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents gain in adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab. 2008;93: 139146.
  • Anderson FH, Francis RM, Faulkner K.. Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone. 1996;18: 171177.
  • Araujo AB, Kupelian V., Page ST, Handelsman DJ, Bremner WJ, McKinlay JB. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med. 2007;167: 12521260.
  • Bagatell CJ, Heiman J.R., Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high dose exogenous testosterone in healthy men. J Clin Endocrinol Metab. 1994;79: 561567.
  • Barrett-Connor E.. Lower endogenous androgen levels and dyslipidemia in men with non—insulin-dependent diabetes mellitus. Ann Internal Med. 1992;117: 807811.
  • Barrett-Connor E.. Andropause and intima media-thickness. J Am Coll Cardio. 2005;45: 16091610.
  • Barrett-Connor E., Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation. 1988;78: 539545.
  • Barud W., Palusinski R., Beltkowski J., Wojcicka G.. Inverse relationship between total testosterone and anti-oxidized low density lipoprotein antibody levels in ageing males. Atherosclerosis. 2002;164: 282288.
  • Basaria S.. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl. 2008;29: 534539.
  • Basaria S., Dobs A.. Hypogonadism and androgen replacement therapy in elderly men. Am J Med. 2001;110: 563572.
  • Basaria S., Dobs AS. Testosterone making an entry into the cardiometabolic world. Circulation. 2007;116: 26582661.
  • Basaria S., Muller D., Carducci M., Egan J., Dobs A.. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106: 581588.
  • Benten WP, Lieberherr M., Stamm O., Wrehlke C., Guo Z., Wunderlich F.. Testosterone signaling through internalizable surface receptors in androgen receptor—free macrophages. Mol Biol Cell. 1999;10: 31133123.
  • Cairrão E., Alvarez E., Santos-Silva AJ, Verde I.. Potassium channels are involved in testosterone-induced vasorelaxation of human umbilical artery. Naunyn Schmiedebergs Arch Pharmacol. 2008;376: 375383.
  • Calles-Escandon J., Mirza SA, Sobel BE, Schneider DJ. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes. 1998;47: 290293.
  • Carrero JJ, Qureshi AR, Parini P., Arver S., Lindholm B., Bárány P., Heimbürger O., Stenvinkel P.. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol. 2009;20: 613620.
  • Chen KC, Peng CC, Hsieh HM, Peng CH, Hsieh CL, Huang CN, Chyau CC, Wang HE, Peng RY. Antiandrogenic therapy can cause coronary arterial disease. Int J Urol. 2005;12: 886891.
  • Chou TM, Sudhir K., Hutchison SJ, Ko E., Amidon TM, Collins P., Chatterjee K.. Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation. 1996;94: 26142619.
  • Crews JK, Khalil RA. Gender-specific inhibition of Ca2+ entry mechanisms of arterial vasoconstriction by sex hormones. Clin Exp Pharmacol Physiol. 1999;26: 707715.
  • D'Amico A., Denham J., Crook J., Chen MH, Goldhaber S., Lamb D., Joseph D., Tai KH, Malone S., Ludgate C., Steigler A., Kantoff P.. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25: 24202425.
  • de Pergola G., Pannacciulli N., Ciccone M., Tartagni M., Rizzon P., Giorgino R.. Free testosterone plasma levels are negatively associated with the intima-media thickness of the common carotid artery in overweight and obese glucose-tolerant young adult men. Int J Obesity. 2003;27: 803807.
  • Dobrzycki S., Serwatka W., Nadlewski S., Korecki J., Jackowski R., Paruk J., Ladny J.R., Hirnle T.. An assessment of correlations between endogenous sex hormone levels and the extensiveness of coronary heart disease and the ejection fraction of the left ventricle in males. J Med Invest. 2003;50: 162169.
  • Dobs AS, Bachorik PS, Arver S., Meikle AW, Sanders SW, Caramelli KE, Mazer NA. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J Clin Endocrinol and Metab. 2001;86: 10261033.
  • Dockery F., Bulpitt CJ, Agarwal S., Donaldson M., Rajkumar C.. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci. 2003;104: 195201.
  • Dubey RK, Oparil S., Imthurn B., Jackson EK. Sex hormones and hypertension. Cardiovasc Res. 2002;53: 688708.
  • Dunajska K., Milewicz A., Szymczak J., Jedrzejuk D., Kuliczkowski W., Salomon P., Nowicki P.. Evaluation of sex hormone levels and some metabolic factors in men with coronary atherosclerosis. Aging Male. 2004;7: 197204.
  • Emmelot-Vonk MH, Verhaar HJJ, Pour Nakhai HR, Aleman A., Lock TMTW, Bosch Ruud JLH, Grobbee DE, van Der Schouw YT. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older age. A randomized controlled trial. J Am Med Assoc. 2008;299: 3952.
  • English K., Steeds R., Jones T., Diver M., Channer K.. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000;102: 19061911.
  • English KM, Jones RD, Jones TH, Morice AH, Channer KS. Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest. 2002;25: 455458.
  • Er F., Michels G., Brandt MC, Khan I., Haase H., Eicks M., Lindner M., Hoppe UC. Impact of testosterone on cardiac L-type calcium channels and Ca2+sparks: acute actions antagonize chronic effects. Cell Calcium. 2007;41: 467477.
  • Esposito K., Ciotola M., Giugliano F., de Sio M., Giugliano G., D'armiento M., Giugliano D.. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Imp Res. 2006;18: 405410.
  • Fonseca V., Jawa A.. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments? Am J Cardiol. 2005;96: 13M18M.
  • Foresta C., Caretta N., Lana A., de Toni L., Biagioli A., Ferlin A., Garolla A.. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab. 2006;91: 45994602.
  • Foresta C., Zuccarello D., de Toni L., Garolla A., Caretta N., Ferlin A.. Androgens stimulate endothelial progenitor cells through an androgen-mediated pathway. Clin Endo. 2008;68: 284289.
  • Fu L., Gao QP, Shen JX. Relationship between testosterone and indexes indicating endothelial function in male coronary heart disease patients. Asian J Androl. 2008;10: 214218.
  • Fujimoto R., Morimoto I., Morita E., Sugimoto H., Ito Y., Eto S.. Androgen receptors, 5 alpha-reductase activity and androgen-dependent proliferation of vascular smooth muscle cells. J Steroid Biochem Mol Biol. 1994;50: 169174.
  • Fukui M., Kitagawa Y., Nakamura N., Kadono M., Mogami S., Hirata C., Ichio N., Wada K., Hasegawa G., Yoshikawa T.. Concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care. 2003;26: 18691873.
  • Geary G., Krause D., Duckles S.. Gonadal hormones affect diameter of male rat cerebral arteries through endothelium-dependent mechanisms. Am J Physiol Heart Circ Physiol. 2000;279: 610618.
  • Giannattasio C., Failla M., Grappiolo A., Stella ML, Del Bo A., Colombo M., Mancia G.. Fluctuations of radial artery distensibility throughout the menstrual cycle. Arterioscler Thromb Vasc Biol. 1999;19: 19251929.
  • Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Investig. 2000;106: 453458.
  • Gyllenborg J., Rasmussen SL, Borch-Johnsen K., Heitmann BL, Skakkebaek NE, Juul A.. Cardiovascular risk factors in men: the role of gonadal steroids and sex hormone-binding globulin. Metabolism. 2001;50: 882888.
  • Haffner SM, Karhapää P., Mykkänen L., Laakso M.. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes. 1994;43: 212219.
  • Haffner SM. Sex hormones, obesity, fat distribution, type 2diabetes and insulin resistance: epidemiological and clinical correlation. Int J Obes Relat Metab Disord. 2000; (suppl 2): S56S58.
  • Haffner SM, Agostino RD Jr, Saad MF, O'Leary DH, Savage PJ, Rewers M., Selby J., Bergman RN, Mykkänen L.. Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study). Am J Cardiol. 2000;85: 13951400.
  • Haffner SM, Mykkänen L., Valdez RA, Katz MS. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab. 1993;77: 16101615.
  • Haidar A., Yassin A., Saad F., Shabsigh R.. Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male. 2007;10: 189196.
  • Hak A., Witteman J., de Jong F., Geerlings M., Hofman A., Pols H.. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002;87: 36323639.
  • Hakimian P., Blute M. Jr, Kashanian J., Chan S., Silver D., Shabsigh R.. Metabolic and cardiovascular effects of androgen deprivation therapy. BJU Int. 2008;102: 15091514.
  • Hall J., Jones RD, Jones TH, Channer KS, Peers C.. Selective inhibition of L-type Ca2+ channels in A7r5 cells by physiological levels of testosterone. Endocrinology. 2006;147: 26752680.
  • Heufelder AE, Saad F., Bunck MC, Gooren L.. 52-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in hypogonadal men with newly diagnosed type 2 diabetes. J Androl. In press.
  • Higashi Y., Noma K., Yoshizumi M., Kihara Y.. Endothelial function and oxidative stress in cardiovascular diseases. Circ J. 2009;73: 411418.
  • Howell SJ, Radford JA, Adams JE, Smets EM, Warburton R., Shalet SM. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol. 2001;55: 315324.
  • Hutchison SJ, Browne AE, Ko E., Chou TM, Zellner C., Komesaroff PA, Chatterjee K., Sudhir K.. Dehydroepiandrosterone sulfate induces acute vasodilation of porcine coronary arteries in vitro and in vivo. J Cardiovasc Pharmacol. 2005;46: 325332.
  • Isidori AM, Giannetta E., Pozza C., Bonifacio V., Isidori A.. Androgens, cardiovascular disease and osteoporosis. J Endocrinol Invest. 2005;28(suppl 10): 7379.
  • Jackson G.. Testosterone—not just a replacement therapy. Int J Clin Pract. 2006;60: 10211027.
  • Jeppesen LL, Jorgensen HS, Nakayama H., Raaschou HO, Olsen TS, Winther K.. Decreased serum testosterone in men with acute ischemic stroke. Arterioscler Thromb Vasc Biol. 1996;16: 749754.
  • Jones RD, English KM, Jones TH, Channer KS. Testosterone-induced coronary vasodilatation occurs via a non-genomic mechanism: evidence of a direct calcium antagonism action. Clin Sci (Lond). 2004a;107: 149158.
  • Jones RD, Jones T Hugh, Channer KS. The influence of testosterone upon vascular reactivity. Eur J Endocrinol. 2004b;151: 2937.
  • Jones RD, Malkin CJ, Channer KS, Jones TH. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: further supportive data. J Clin Endocrinol Metab. 2003;88: 14031404.
  • Jones RD, Nettleship JE, Kapoor D., Jones HT, Channer KS. Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs. 2005;5: 141154.
  • Kang SM, Jang Y., Kim JY, Chung N., Cho SY, Chae JS, Lee JH. Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol. 2002;89: 862864.
  • Kapoor D., Goodwin E., Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154: 899906.
  • Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24: 44484456.
  • Khatana SAM, Taveira TH, Miner MM, Eaton CB, Wu W-C. Does cardiovascular risk reduction alleviate erectile dysfunction in men with type II diabetes mellitus? Int J Imp Res. 2008;20: 501506.
  • Khaw K., Dowsett M., Folkerd E., Bingham S., Wareham N., Luben R., Welch A., Day N.. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation. 2007;116: 26942701.
  • Kim J., Montagnani M., Koh K., Quon M.. Reciprical relationships between insulin resistance and endothelial dysfunction. Circulation. 2006;113: 18881904.
  • Kouloumenta V., Hatziefthimiou A., Paraskeva E., Gourgoulianis K., Molyvdas PA. Non-genomic effect of testosterone on airway smooth muscle. Br J Pharmacol. 2006;149: 10831091.
  • Kumanov P., Tomova A., Kirilov G., Dakovska L., Schinkov A.. Increased plasma endothelin levels in patients with male hypogonadism. Andrologia. 2002;34: 2933.
  • Laaksonen DE, Niskanen L., Punnonen K., Nyyssonen K., Tuomainen TP, Salonen R., Rauramaa R., Salonen JT. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol. 2003;149: 601608.
  • Laughlin GA, Barrett-Connor E., Bergstrom J.. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93: 6875.
  • Lichtenstein MJ, Yarnell JW, Elwood PC, Beswick AD, Sweetnam PM, Marks V., Teale D., Riad-Fahmy D.. Sex hormones, insulin, lipids, and prevalent ischemic heart disease. Am J Epidemiol. 1987;126: 647657.
  • Liu D., Dillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem. 2002;277: 2137921388.
  • Liu D., Dillon JS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids. 2004;69: 279289.
  • Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endo Rev. 2003;24: 313340.
  • Lu YL, Kuang L., Zhu H., Wu H., Wang XF, Pang YP, Wang NJ, Yu DL. Changes in aortic endothelium ultrastructure in male rats following castration, replacement with testosterone and administration of 5-alpha-reductase inhibitor. Asian J Androl. 2007;9: 843847.
  • Lu-Yao GL, Albertsen PC, Moore DF, Shih W., Lin Y., DiPaola RS, Yao SL. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300: 173181.
  • Ly LP, Jimenez M., Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab. 2001;86: 40784088.
  • Maggio M., Basaria S., Ble A., Lauretani F., Bandinelli S., Ceda G., Valenti G., Ling S., Ferrucci L.. Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. J Clin Endocrinol Metab. 2006;91: 345347.
  • Maggio M., Lauretani F., Ceda GP, Bandinelli S., Ling SM, Metter EJ, Artoni A., Carassale L., Cazzato A., Ceresini G., Guralnik JM, Basaria S., Valenti G., Ferrucci L.. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med. 2007;167: 22492254.
  • Makhsida N., Shah J., Yan G., Fisch H., Shabsigh R.. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005;174: 827834.
  • Mäkinen J., Jarvisalo M., Pollanen P., Perheentupa A., Irjala K., Koskenvuo M., Mäkinen J., Huhtaniemi I., Raitakari O.. Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol. 2005;45: 16031608.
  • Mäkinen JI, Perheentupa A., Irjala K., Pöllänen P., Mäkinen J., Huhtaniemi I., Raitakari OT. Endogenous testosterone and serum lipids in middle-aged men. Atherosclerosis. 2008;197: 688693.
  • Malkin CJ, Jones RD, Jones TH, Channer KS. Effect of testosterone on ex vivo vascular reactivity in man. Clin Sci (Lond). 2006a;111: 265274.
  • Malkin CJ, Jones TH, Channer KS. The effect of testosterone on insulin sensitivity in men with heart failure. Eur J Heart Fail. 2007;9: 4450.
  • Malkin CJ, Morris PD, Pugh PJ, English KM, Channer KS. Effect of testosterone therapy on QT dispersion in men with heart failure. Am J Cardiol. 2003a;92: 12411243.
  • Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a protective factor against atherosclerosis—immunomodulation and influence upon plaque development and stability. J Endocrinol. 2003b;178: 373380.
  • Malkin CJ, Pugh PJ, Jones RD, Kapoor D., Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004a;89: 33133318.
  • Malkin CJ, Pugh PJ, Jones TH, Channer KS. Testosterone for secondary prevention in men with ischaemic heart disease? QJM. 2003c;96: 521529.
  • Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, Channer KS. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004b;90: 871876.
  • Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2006b;27: 5764.
  • Mårin P.. Testosterone and regional fat distribution. Obes Res. 1995;3(suppl 4): S609S612.
  • Mårin P., Holmang S., Gustafsson C., Jonsson L., Kvist H., Elander A., Eldh J., Sjostrom L., Holm G., Bjorntorp P.. Androgen treatment of abdominally obese men. Obes Res. 1993;1: 245251.
  • Mårin P., Lonn L., Andersson B., Oden B., Olbe L., Bengtsson BA, Bjorntorp P.. Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues in vivo in men: effects of testosterone. J Clin Endocrinol Metab. 1996;81: 10181022.
  • McVeigh GE, Cohn JN. Endothelial dysfunction and the metabolic syndrome. Curr Diabetes Rep. 2003;3: 8792.
  • Miller VM, Mulvagh SL. Sex steroids and endothelial function: translating basic science to clinical practice. Trends Pharmacol Sci. 2007;28: 263270.
  • Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol. 1999;31: 6174.
  • Montagnana M., Lippi G.. Relationship between serum testosterone and cardiovascular risk profile in the general population. Arch Intern Med. 2008;23: 168: 1350–1351.
  • Montaño LM, Calixto E., Figueroa A., Flores-Soto E., Carbajal V., Perusquía M.. Relaxation of androgens on rat thoracic aorta: testosterone concentration dependent agonist/antagonist L-type Ca2+ channel activity, and 5beta-dihydrotestosterone restricted to L-type Ca2+ channel blockade. Endocrinology. 2008;149: 25172526.
  • Muller M., Grobbee DE, den Tonkelaar I., Lamberts SWJ, van Der Schouw YT. Endogenous sex hormones and metabolic syndrome in ageing men. J Clin Endocrinol Metab. 2005;90: 26182623.
  • Muller M., van den Beld A., Bots M., Grobbee D., Lamberts S., van Der Schouw Y.. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004;109: 20742079.
  • Murphy JG, Khalil RA. Decreased [Ca(2+)](i) during inhibition of coronary smooth muscle contraction by 17beta-estradiol, progesterone, and testosterone. J Pharmacol Exp Ther. 1999;291: 4452.
  • Nakao J., Chang W-C, Murota S-I, Orimo H.. Testosterone inhibits prostacyclin production by rat aortic smooth muscle cells in culture. Atherosclerosis. 1981;39: 203209.
  • Navarro-Dorado J., Orensanz LM, Recio P., Bustamante S., Benedito S., Martínez AC, García-Sacristán A., Prieto D., Hernández M.. Mechanisms involved in testosterone-induced vasodilatation in pig prostatic small arteries. Life Sci. 2008;83: 569573.
  • Nesto RW. Comprehensive clinical assessment of modifiable cardiometabolic risk factors. Clin Cornerstone. 2008;9(suppl 1): S9S19.
  • Nishiyama T., Ishizaki F., Anraku T., Shimura H., Takahashi K.. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90: 657660.
  • Oh JY, Barrett-Connor E., Wedick NM, Wingard DL; Rancho Bernardo Study. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernard study. Diabetes Care. 2002;25: 5560.
  • Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90: 15021510.
  • Perusquía M., Navarrete E., González L., Villalón CM. The modulatory role of androgens and progestins in the induction of vasorelaxation in human umbilical artery. Life Sci. 2007;81: 9931002.
  • Perusquía M., Navarrete E., Jasso-Kamel J., Montaño LM. Androgens induce relaxation of contractile activity in pregnant human myometrium at term: a nongenomic action on L-type calcium channels. Biol Reprod. 2005;73: 214221.
  • Phillips G., Pinkernell B., Jing T.. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb. 1994;14: 701706.
  • Phillips GB, Jing TY, Resnick LM, Barbagallo M., Laragh JH, Sealey JE. Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension. J Hypertens. 1993;11: 699702.
  • Pitteloud N., Hardin M., Dwyer AA, Valassi E., Yialamas M., Elahi D., Hayes FJ. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005;90: 26362641.
  • Platz EA. Low testosterone and risk of premature death in older men: analytical and preanalytical issues in measuring circulating testosterone. Clin Chem. 2008;54: 11101112.
  • Polderman KH, Stehouwer CDA, van Kamp GJ, Dekker GA, Verheugt FWA, Gooren LJG. Influence of sex hormones on plasma endothelin levels. Ann Intern Med. 1993;118: 429432.
  • Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res. 1999;59: 41614164.
  • Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. Heart. 2004;90: 446447.
  • Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J. 2003;24: 909915.
  • Reaven GM, Lithell H., Landsberg L.. Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334: 374381.
  • Roddam AW, Allen NE, Appleby P., Key TJ. Endogenous Hormones, Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100: 170183.
  • Saad F., Gooren L., Haider A., Yassin A.. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl. 2007;53: 353357.
  • Saad F., Gooren LJ, Haider A., Yassin A.. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl. 2008;29: 102105.
  • Sader MA, Griffiths KA, Skilton MR, Wishart SM, Handelsman DJ, Celermajer DS. Physiological testosterone replacement and arterial endothelial function in men. Clin Endocrinol (Oxf). 2003;59: 6267.
  • Sader MA, McCredie RJ, Griffiths KA, Wishart SM, Handelsman DJ, Celermajer DS. Oestradiol improves arterial endothelial function in healthy men receiving testosterone. Clin Endocrinol (Oxf). 2001;54: 175181.
  • Scragg JL, Dallas ML, Peers C.. Molecular requirements for L-type Ca2+ channel blockade by testosterone. Cell Calcium. 2007;42: 1115.
  • Scragg JL, Jones RD, Channer KS, Jones TH, Peers C.. Testosterone is a potent inhibitor of L-type Ca2+ channels. Biochem Biophys Res Commun. 2004;318: 503506.
  • Seyrek M., Yildiz O., Ulusoy HB, Yildirim V.. Testosterone relaxes isolated human radial artery by potassium channel opening action. J Pharmacol Sci. 2007;103: 309316.
  • Shahani S., Braga-Basaria M., Basaria S.. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab. 2008;93: 20422049.
  • Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Int Med. 2006;166: 16601665.
  • Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Int Med. 2006;166: 16601665.
  • Simon D., Charles MA, Nahoul K., Orssaud G., Kremski J., Hully V., Joubert E., Papoz L., Eschwege E.. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab. 1997;82(2): 682685.
  • Simoncini T., Mannella P., Fornari L., Caruso A., Varone G., Genazzani AR. Genomic and non-genomic effects of estrogens on endothelial cells. Steroids. 2004;69: 537542.
  • Smith G., Ben-Shlomo Y., Beswick A., Yarnell J., Lightman S., Elwood P.. Cortisol, testosterone, and coronary heart disease prospective evidence from the Caperhilly Study. Circulation. 2005;112: 332340.
  • Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes. 2007a;14: 247254.
  • Smith MR. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res. 2007b;13: 241245.
  • Smith MR. Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Curr Urol Rep. 2008;9: 197202.
  • Smith MR, Bennett S., Evans L., Kynaton H., Parmar M., Mason M., Cockcroft J., Scanlon M., Davies J.. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86: 42614267.
  • Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87: 599603.
  • Smith MR, Lee H., Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91: 13051308.
  • Sobel BE. Insulin resistance and thrombosis: a cardiologist's view. Am J Cardiol. 1999;84: 37J41J.
  • Sochorová R., Mosnárová A., Huzuláková I.. The possible influence of testosterone on calcium ion transport (investigated) in guinea pig uterus. Acta Physiol Hung. 1991;77: 1924.
  • Stattin P., Lumme S., Tenkanen L., Alfthan H., Jellum E., Hallmans G., Thoresen S., Hakulinen T., Luostarinen T., Lehtinen M., Dillner J., Stenman UH, Hakama M.. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer. 2004;108: 418424.
  • Svartberg J.. Review: epidemiology: testosterone and the metabolic syndrome. Int J Impot Res. 2007;19: 124128.
  • Svartberg J., vo Muhlen D., Schirmer H., Barrett-Connor E., Sundfjord J., Jorde R.. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study. Eur J Endocrinol. 2004a;150: 6571.
  • Svartberg J., vo Muhlen D., Sundsfjord J., Jorde R.. Waist circumference and testosterone levels in community dwelling men. The Tromso Study. Eur J Epidemiol. 2004b;19: 657663.
  • Swerdloff RS, Wang C.. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male. 2003;6: 207211.
  • Tan KC, Shiu SW, Pang RW, Kung AW. Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins. Clin Endocrinol (Oxf). 1998;48: 187194.
  • Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metabol. 1992;75: 10921088.
  • Tep-Areenan P., Kendall DA, Randall MD. Mechanisms of vasorelaxation to testosterone in the rat aorta. Eur J Pharmacol. 2003;465: 125132.
  • Thompson PD, Cullinane EM, Sady SP, Chenevert C., Saritelli AL, Sady MA, Herbert PN. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA. 1989;261: 11651168.
  • Tortosa A., Bes-Rastrollo M., Sanchez-Villegas A., Basterra-Gortari FJ, Nunez-Cordoba JM, Martinez-Gonzalez MA. Mediterranean diet inversely associated with the incidence of metabolic syndrome. Diabetes Care. 2007;30: 29572959.
  • Traish AM, Abu-Zahra H., Guay AT. The brain, the penis and steroid hormones: clinical correlates with endothelial dysfunction. Curr Pharm Des. 2008;14: 37233736.
  • Traish AM, Guay AT, Feeley R., Saad F.. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl. 2009a;30(1): 1022.
  • Traish AM, Saad F., Guay AT. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl. 2009b;30(1): 2332.
  • Travis RC, Key TJ, Allen NE, Appleby PN, Roddam AW, et al. Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2007;121: 13311338.
  • Tripathy D., Shah P., Lakshmy R., Reddy KS. Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotropic hypogonadism. Hormone Metab Res. 1998;30: 642645.
  • Uyanik BS, Ari Z., Gümüs B., Yiǧitoǧlu MR, Arslan T.. Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. Jpn Heart J. 1997;38: 7382.
  • van Pottelbergh I., Braeckman L., de Bacquer D., de Backer G., Kaufman J.. Potential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis. 2003;166: 95102.
  • Webb C., Elkington A., Kraidly M., Keenan N., Pennell D., Collins P.. Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol. 2008;101: 618624.
  • Webb CM, Adamson DL, de Zeigler D., Collins P.. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol. 1999;83: 437439.
  • Wu FC, vo Eckardstein A.. Androgens and coronary artery disease. Endocr Rev. 2003;24: 183217.
  • Yannucci J., Manola J., Garnick MB, Bhat G., Bubley GJ. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol. 2006;176: 520525.
  • Yialamas MA, Dwyer AA, Hanley E., Lee H., Hayes Pitteloud FJ. Acute steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2007;92: 42544259.
  • Yildiz O., Seyrek M.. Vasodilating mechanisms of testosterone. Exp Clin Endocrinol Diabetes. 2007;115: 16.
  • Yildiz O., Seyrek M., Gul H., Un I., Yildirim V., Ozal E., Uzun M., Bolu E.. Testosterone relaxes human internal mammary artery in vitro. J Cardiovasc Pharmacol. 2005;45: 580585.
  • Yue P., Chatterjee K., Beale C., Poole-Wilson PA, Collins P.. Testosterone relaxes rabbit coronary arteries and aorta. Circulation. 1995;91: 11541160.
  • Yung LM, Leung FP, Yao X., Chen ZY, Huang Y.. Reactive oxygen species in vascular wall. Cardiovasc Hematol Disord Drug Targets. 2006;6: 119.
  • Zgliczynski S., Ossowski M., Slowinska-Srzednicka J., Brzezinska A., Zgliczynski W., Soszynski P., Chotkowska E., Srzednicki M., Sadowski Z.. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis. 1996;121: 3543.
  • Zitzmann M., Nieschlag E.. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long term intramuscular testosterone undecanoae therapy in hypogonadal men. J Clin Endocrinol Metab. 2007;92: 38443853.
  • Zmuda JM, Cauley JA, Kriska A., Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men: a 13 year follow-up of former multiple risk factor intervention trial participants. Am J Epidemiol. 1997;146: 609617.